Fig. 8.

Efficacy of RAC1 inhibitor and paclitaxel combination therapy in lung cancer cells. a Cell viability in the presence of increased concentration of EHop-016, a RAC1 inhibitor. b Growth curve of lung cancer cells treated with different concentrations of EHop-016 (1.0–5 μmol/L for 48 h). IC₅₀ of EHop-016 for different lung cancer cell lines was determined according to their growth curve. c Western blot analysis of active RAC1 in lung cancer cells after treatment with EHop-016. d The inhibition efficacy of siLCAT1 and control cells under different concentrations of EHop-016. Cell viability was used to evaluate the inhibition efficacy of EHop-016. e Cell viability after paclitaxel treatment (0.1–100 nmol/L for 48 h). f Efficacy of EHop-016 (5.0 μmol/L for Calu1 and HOP62, 9 μmol/L for A549) and paclitaxel (6 nmol/L) combination therapy in lung cancer cells. The cell viability of lung cancer cells was measured after treatment for 48 h using CCK8 assays. g Proposed model for LCAT1-mediated regulation of proliferation, migration, and invasion in lung cancer cells